Hypertension, Insulin Resistance, Metabolic Syndrome
Conditions
Keywords
Montmorency Tart Cherry, Anthocyanins, Polyphenols, Metabolic Syndrome, Insulin Resistance, Hypertension, Lipid Profile
Brief summary
The present study examined the effect of Montmorency tart cherry juice and capsules on functional and blood-based cardio-metabolic markers in humans with Metabolic Syndrome. Participants received a single bolus of Montmorency tart cherry juice, Montmorency tart cherry capsules and placebo in a random, crossover trial. Outcome variables were measured immediately pre- and up to 5 hours post-bolus. It was hypothesised that Montmorency tart cherry juice and capsules would improve cardio-metabolic markers. Furthermore, it was hypothesised that Montmorency tart cherry capsules would be more beneficial than Montmorency tart cherry juice due to increased bioavailability of phytochemicals.
Interventions
DIETARY_SUPPLEMENTMontmorency Tart Cherry Capsules
Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.
DIETARY_SUPPLEMENTMontmorency Tart Cherry Juice
100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water. Concentrate contains no sweeteners, preservatives, flavourings or added sugar.
DIETARY_SUPPLEMENTPlacebo
130ml serving Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml).
Sponsors
Heart UK
University of Hertfordshire
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Non-smoker, Meet 3 of 5 criteria for Metabolic Syndrome based on National Cholesterol Education Program-Adult Treatment Panel III guidelines: 1. Waist Circumference: \>102cm (men), \>88cm (women) 2. Fasting Serum Triglycerides: ≥1.69 mmol.L-1 3. Fasting High Density Lipoprotein: \<1.03 mmol.L-1 (men), \<1.29 mmol.L-1 (women) 4. Blood Pressure: ≥130 mmHg SBP or ≥85 mmHg DBP 5. Fasting Plasma Glucose: ≥6.1 mmol.L-1
Exclusion criteria
* Current or previous history of gastrointestinal, cardiovascular, hepatic or renal disease, currently diagnosed with diabetes or uncontrolled hypertension (≥160/100 mmHg), allergy to maltodextrin or specific fruit products and those currently taking medication (such as steroids, NSAIDs, antibiotics, antihypertensive, hypoglycaemic, lipid-lowering drugs) or currently using any nutritional or antioxidant supplement. Heavy alcohol consumption (\>14 units per week).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Fasting Insulin | Pre-Bolus and Post-Bolus (1hr, 3hr, 5hr) |
| Change in Fasting Lipid Profile (Total Cholesterol, HDL, Triglycerides, LDL) | Pre-Bolus and Post-Bolus (1hr, 3hr, 5hr) |
| Change in Fasting Glucose | Pre-Bolus and Post-Bolus (1hr, 3hr, 5hr) |
| Change in Systolic and Diastolic Blood Pressure | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Stroke Volume | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) | Beat-to-beat resting cardiac haemodynamics |
| Change in Heart Rate | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) | Beat-to-beat resting cardiac haemodynamics |
| Change in Mean Arterial Pressure | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) | Beat-to-beat resting cardiac haemodynamics |
| Change in Augmentation Index | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) | Measure of arterial stiffness and central blood pressures |
| Change in Resting Energy Expenditure | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) | Measured from indirect calorimetry |
| Change in Respiratory Quotient | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) | Measured from indirect calorimetry |
| Change in Total Peripheral Resistance | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) | Beat-to-beat resting cardiac haemodynamics |
| Change in Aortic Systolic and Diastolic Pressure | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) | Measure of arterial stiffness and central blood pressures |
| Change in Augmentation Pressure | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) | Measure of arterial stiffness and central blood pressures |
| Change in Cardiac Output | Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr) | Beat-to-beat resting cardiac haemodynamics (cardiac output, mean arterial pressure, strove volume, total peripheral resistance, heart rate) |
Countries
United Kingdom
Outcome results
None listed